Breaking News Instant updates and real-time market news.

VZ

Verizon

$60.35

-0.13 (-0.21%)

, T

AT&T

$38.94

0.45 (1.17%)

05:56
11/04/19
11/04
05:56
11/04/19
05:56

Nomura Instinet downgrades Verizon to Neutral after AT&T price cuts

Nomura Instinet analyst Jeffrey Kvaal downgraded Verizon Communications (VZ) to Neutral from Buy with a price target of $65, down from $67. The stock closed Friday down 11c to $60.37. AT&T's (T) new price reductions, and T-Mobile's (TMUS) likely response, reduces visibility into Verizon's near-term growth trajectory, Kvaal tells investors in a research note. The analyst now has lower confidence into Verizon's long-term ability to lift pricing for 5G. While he prefers wireless over fixed over time, he moves to a Neutral stance on Verizon.

VZ

Verizon

$60.35

-0.13 (-0.21%)

T

AT&T

$38.94

0.45 (1.17%)

TMUS

T-Mobile

$82.46

-0.21 (-0.25%)

  • 04

    Nov

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 29

    Jan

  • 30

    Jan

VZ Verizon
$60.35

-0.13 (-0.21%)

11/04/19
NOMU
11/04/19
DOWNGRADE
Target $65
NOMU
Neutral
Verizon downgraded to Neutral from Buy at Nomura Instinet
Nomura Instinet analyst Jeffrey Kvaal downgraded Verizon Communications to Neutral from Buy with a $65 price target.
10/25/19
MOFT
10/25/19
NO CHANGE
Target $57
MOFT
Neutral
MoffettNathanson sees 'worrisome signs' in Verizon's Q3 report
MoffettNathanson analyst Craig Moffett said Verizon still has the industry's highest margins and still boasts the industry's lowest post-paid phone churn rate, but he points to what he sees as "a few worrisome signs" in Verizon's Q3 report despite the company's "solid" subscriber growth metrics. Wireless service margins have started to ease, ARPU growth moved lower for a second straight quarter and churn "has started to move ever so slightly higher," Moffett tells investors in a post-earnings research note. Most "ominously," Verizon is no longer the hands-down winner of the "best network" test, which is now a much more nuanced discussion, according to Moffett, who keeps a Neutral rating and $57 price target on the stock.
10/28/19
GUGG
10/28/19
NO CHANGE
Target $69
GUGG
Buy
Verizon price target raised to $69 from $65 at Guggenheim
Guggenheim analyst Mike McCormack raised his price target for Verizon Communications to $69 from $65 saying the company reported "strong" Q3 Wireless results, with revenue, earnings, and free cash flow coming in ahead of consensus. The analyst maintains a Buy rating on the shares.
10/28/19
ADAM
10/28/19
NO CHANGE
Target $8.5
ADAM
Buy
Inseego price target raised to $8.50 from $7.00 at Canaccord
Canaccord analyst T. Michael Walkley raised his price target on Inseego (INSG) to $8.50 from $7.00. Management decided to increase near-term investments to support additional products for a growing global 5G opportunity. The company launched the industry's first 5G mobile hotspot and Walkley believes volumes will ramp through year-end as Verizon (VZ) launches an increasing number of cities.Walkley reiterated his Buy rating on Inseego shares.
T AT&T
$38.94

0.45 (1.17%)

10/29/19
RHCO
10/29/19
NO CHANGE
Target $36
RHCO
Hold
AT&T price target raised to $36 from $31 at SunTrust
SunTrust analyst Greg Miller raised his price target on AT&T to $36 after its Q3 earnings beat along with its response to Elliott Advisors with a multi-year plan to reduce cost, buy back stock, and lower debt. The analyst is keeping his Hold rating however, noting that the company's targets may not be "achievable" amid the continued competition in multiple areas of its business as well as the secular headwind in its video operations.
11/01/19
JPMS
11/01/19
NO CHANGE
Target $42
JPMS
Overweight
AT&T price target raised to $42 from $39 at JPMorgan
JPMorgan analyst Philip Cusick raised his price target for AT&T to $42 from $39 after layering in HBO Max estimates to his model and given the company some benefit for additional cost cutting. The analyst looks for domestic HBO/Max subscribers to go from 34M in 2020 to 47M by 2025. He feels AT&T shares still look attractive and keeps an Overweight rating on the name.
10/16/19
10/16/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Verizon (VZ), Comcast (CMCSA), and AT&T (T) initiated with Market Perform ratings at Bernstein. 2. Inovalon (INOV) initiated with a Buy at Citi. 3. Assembly Biosciences (ASMB) initiated with a Buy at Mizuho. 4. ChromaDex (CDXC) initiated with an Outperform at Oppenheimer. 5. Axsome Therapeutics (AXSM) initiated with a Buy at Guggenheim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/01/19
STPT
11/01/19
DOWNGRADE
STPT
Hold
AT&T downgraded to Hold from Buy at Standpoint Research
Standpoint Research analyst Ronnie Moas downgraded AT&T to Hold from Buy.
TMUS T-Mobile
$82.46

-0.21 (-0.25%)

11/01/19
COWN
11/01/19
NO CHANGE
Target $260
COWN
Outperform
American Tower price target raised to $260 from $238 at Cowen
Cowen analyst Colby Synesael raised his price target on American Tower (AMT) to $260 from $238 following in-line Q3 results. The analyst said the recent India situation as well as the pending T-Mobile (TMUS)/Sprint (S) merger creates near-term uncertainty but he views the recent selloff as a buying opportunity. He expects more meaningful upside in 2020 when the India and merger situations are resolved. Synesael maintained his Outperform rating on American Tower shares.
10/29/19
COWN
10/29/19
NO CHANGE
Target $87
COWN
Outperform
T-Mobile price target lowered to $87 from $93 at Cowen
Cowen analyst Colby Synesael lowered his price target on T-Mobile to $87 from $93 following good Q3 results and raised 2019 postpaid net adds/EBITDA. The analyst said momentum continues on market segmentation and network improvement but he feels the near-term upside is limited although he would be a buyer on any weakness. Synesael reiterated his Outperform rating on T-Mobile shares.
10/29/19
RHCO
10/29/19
NO CHANGE
Target $95
RHCO
Buy
T-Mobile price target raised to $95 from $80 at SunTrust
SunTrust analyst Greg Miller raised his price target on T-Mobile (TMUS) to $95 and kept his Buy rating, saying the company's Q3 results continue to "demonstrate strength" of its "UnCarrier strategy" and its ability to capture market share in a more "competitive and mature" market place. The analyst further states that he remains optimistic that the company's can close its Sprint (S) merger with only an approval by federal regulators and contends that T-Mobile remains among "best" in the space.
10/16/19
BERN
10/16/19
INITIATION
Target $63
BERN
Market Perform
Verizon initiated with a Market Perform on competition at Bernstein
As previously reported, Bernstein analyst Peter Supino initiated coverage of Verizon (VZ) with a Market Perform rating and $63 price target. The analyst notes that Verizon is the mobile industry leader with an "exciting" network vision and upside to its dividend payout ratio. However, he believes the networks of AT&T (T) and T-Mobile (TMUS) are increasingly competitive and he has longer-term concerns about an intensification of MVNO-competition. With strong near-term mix tends, long-term potential for new revenues from 5GHome and Enterprise, the risk-reward seems balanced, he contends.

TODAY'S FREE FLY STORIES

EXPE

Expedia

$107.58

1.9 (1.80%)

08:26
12/07/19
12/07
08:26
12/07/19
08:26
Periodicals
Expedia shares still a buy despite management changes, Barron's says »

Shares of Expedia remain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

, CODI

Compass Diversified

$23.88

0.45 (1.92%)

08:21
12/07/19
12/07
08:21
12/07/19
08:21
Periodicals
Darling, Qualys among small-caps to own for 2020 breakout, Barron's says »

In its weekend cover…

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

CODI

Compass Diversified

$23.88

0.45 (1.92%)

QLYS

Qualys

$85.37

-0.37 (-0.43%)

LECO

Lincoln Electric

$92.52

0.69 (0.75%)

HASI

Hannon Armstrong

$29.50

0.24 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 12

    Dec

CBMG

Cellular Biomedicine

$17.56

0.18 (1.04%)

08:11
12/07/19
12/07
08:11
12/07/19
08:11
Hot Stocks
Cellular Biomedicine presents first clinical data of C-CAR088 in myeloma »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AXLA

Axcella

$3.63

-0.83 (-18.61%)

08:07
12/07/19
12/07
08:07
12/07/19
08:07
Hot Stocks
Axcella says preclinical of AXA4010 data show multifactorial potential »

Axcella Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXLA

Axcella

$3.63

-0.83 (-18.61%)

08:07
12/07/19
12/07
08:07
12/07/19
08:07
Hot Stocks
Axcella says preclinical of AXA4010 data show multifactorial potential »

Axcella Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$47.68

0.06 (0.13%)

08:04
12/07/19
12/07
08:04
12/07/19
08:04
Hot Stocks
AstraZeneca says Calquence combination improved survival in leukemia patients »

AstraZeneca presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:01
12/07/19
12/07
08:01
12/07/19
08:01
Hot Stocks
AbbVie announces follow-up data from chronic lymphocytic leukemia study »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

07:56
12/07/19
12/07
07:56
12/07/19
07:56
Hot Stocks
AbbVie announces data from Phase 2 lymphocytic leukemia study »

AbbVie announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

07:51
12/07/19
12/07
07:51
12/07/19
07:51
Hot Stocks
Janssen announces initial results from Phase 1b/2 multiple myeloma study »

Janssen Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 21

    Jan

XBIT

XBiotech

$11.11

0.1 (0.91%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

07:46
12/07/19
12/07
07:46
12/07/19
07:46
Hot Stocks
XBiotech sells bermekimab to Janssen for $750M plus potential milestones »

XBiotech (XBIT) announced…

XBIT

XBiotech

$11.11

0.1 (0.91%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 21

    Jan

PCG

PG&E

$9.65

-0.13 (-1.33%)

07:39
12/07/19
12/07
07:39
12/07/19
07:39
Hot Stocks
PG&E to amend and finalize bankruptcy plan following settlement »

PG&E said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

PCG

PG&E

$9.65

-0.13 (-1.33%)

07:39
12/07/19
12/07
07:39
12/07/19
07:39
Hot Stocks
PG&E to amend and finalize bankruptcy plan following settlement »

PG&E said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

PCG

PG&E

$9.65

-0.13 (-1.33%)

07:37
12/07/19
12/07
07:37
12/07/19
07:37
Hot Stocks
PG&E announces $13.5B settlement with victims of California wildfires »

PG&E Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

07:34
12/07/19
12/07
07:34
12/07/19
07:34
Hot Stocks
Amazon leases 335,000 square feet of office space in New York City »

Amazon.com signed a lease…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$335.85

5.6 (1.70%)

07:31
12/07/19
12/07
07:31
12/07/19
07:31
Hot Stocks
Tesla CEO Musk cleared in defamation suit over tweet »

A Los Angeles jury on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

ATRC

AtriCure

$30.99

1.29 (4.34%)

04:55
12/07/19
12/07
04:55
12/07/19
04:55
Conference/Events
AtriCure management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACAD

Acadia

$51.37

0.915 (1.81%)

, AMGN

Amgen

$233.74

0.3 (0.13%)

04:55
12/07/19
12/07
04:55
12/07/19
04:55
Conference/Events
Clinical Trials on Alzheimer's Disease to hold conference »

12th Clinical Trials on…

ACAD

Acadia

$51.37

0.915 (1.81%)

AMGN

Amgen

$233.74

0.3 (0.13%)

AZN

AstraZeneca

$47.68

0.06 (0.13%)

BIIB

Biogen

$300.27

0.98 (0.33%)

CLB

Core Laboratories

$46.19

1.94 (4.38%)

DNA

Bought by RHHBY

$0.00

(0.00%)

ESALY

Eisai

$0.00

(0.00%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

LLY

Eli Lilly

$119.59

-0.175 (-0.15%)

MRK

Merck

$88.84

0.09 (0.10%)

NVS

Novartis

$92.08

0.42 (0.46%)

RHHBY

Roche

$0.00

(0.00%)

TAK

Takeda Pharmaceutical

$20.27

-0.16 (-0.78%)

VCNX

Vaccinex

$4.95

-0.05 (-1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 10

    Dec

  • 11

    Dec

  • 16

    Dec

  • 17

    Dec

  • 21

    Jan

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 05

    Feb

  • 14

    Mar

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

04:55
12/07/19
12/07
04:55
12/07/19
04:55
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

04:55
12/07/19
12/07
04:55
12/07/19
04:55
Conference/Events
JPMorgan enterprise software analyst to hold an analyst/industry conference call »

Software Analyst Murphy,…

RUHN

Ruhnn

$6.19

-0.2 (-3.13%)

04:55
12/07/19
12/07
04:55
12/07/19
04:55
Conference/Events
Ruhnn management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

FITB

Fifth Third

$30.24

0.365 (1.22%)

, CSCO

Cisco

$43.83

0.29 (0.67%)

18:37
12/06/19
12/06
18:37
12/06/19
18:37
Hot Stocks
Fifth Third issues statement on temporary network outage »

Fifth Third Bank (FITB)…

FITB

Fifth Third

$30.24

0.365 (1.22%)

CSCO

Cisco

$43.83

0.29 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 08

    Jan

  • 12

    Feb

STML

Stemline

$10.33

0.5 (5.09%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

18:33
12/06/19
12/06
18:33
12/06/19
18:33
Hot Stocks
Stemline names Robert Francomano as Chief Commercial Officer »

Most recently, Francomano…

STML

Stemline

$10.33

0.5 (5.09%)

PFE

Pfizer

$38.29

0.26 (0.68%)

GSK

GlaxoSmithKline

$45.51

0.29 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

GOL

Gol Linhas

$17.39

1.07 (6.56%)

18:31
12/06/19
12/06
18:31
12/06/19
18:31
Hot Stocks
Gol Linhas announces preliminary traffic figures for November »

GOL's domestic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVB

Navidea

$0.97

0.07 (7.78%)

18:25
12/06/19
12/06
18:25
12/06/19
18:25
Syndicate
Navidea announces $1.9M private placement »

Navidea announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFC

Ellington Financial

$18.22

0.09 (0.50%)

18:23
12/06/19
12/06
18:23
12/06/19
18:23
Hot Stocks
Ellington Financial reports estimated book value per share $18.51 on November 30 »

This estimate includes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.